Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.70 |
| ▸ | JAK2 | O60674 | 19/20 | 0.70 |
| ▸ | TYK2 | P29597 | 16/20 | 0.70 |
| ▸ | JAK3 | P52333 | 14/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21382724 | 0.84 | JAK1 (0.59) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL21400278 | 0.84 | JAK2 (0.88) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL23002347 | 0.83 | JAK1 (0.70) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL15077600 | 0.83 | JAK1 (0.70) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL16228177 | 0.83 | JAK1 (0.70) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL16199678 | 0.83 | JAK1 (0.70) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL17500606 | 0.83 | JAK2 (1.00) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL17500608 | 0.83 | JAK2 (1.00) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL21382711 | 0.82 | JAK2 (0.75) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL29708204 | 0.82 | JAK2 (0.75) | JAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768272-B1 | JAK INHIBITORS | LIAO XIBIN (US) | 2025-07-30 | — | — | EP | claimed |
| US-11365188-B2 | JAK inhibitors | LIAO XIBIN (US) | 2022-06-21 | — | — | US | claimed |
| US-20210053943-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2021-02-25 | — | — | US | claimed |
| EP-3768272-A1 | JAK INHIBITORS | Liao, Xibin (US) | 2021-01-27 | — | — | EP | claimed |
| WO-2019182924-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2019-09-26 | — | — | WO | claimed |
| EP-3768272-B1 | JAK INHIBITORS | LIAO XIBIN (US) | 2025-07-30 | — | — | EP | disclosed |
| US-11365188-B2 | JAK inhibitors | LIAO XIBIN (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365188-B2 | JAK inhibitors | LIAO XIBIN (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210053943-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210053943-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3768272-A1 | JAK INHIBITORS | Liao, Xibin (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019182924-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365188-B2 | JAK inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885TYK2 6/4885 |
| US-20210053943-A1 | JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885TYK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.